About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/28/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/28/2021.

Robotic-Assisted Percutaneous Coronary Intervention

Clinicaltrials.gov identifier NCT03927560

Recruitment Status Not yet recruiting

First Posted April 25, 2019

Last update posted May 1, 2019

Study Description

Brief summary:

Percutaneous coronary intervention is a safe procedure. However, its execution is manual, fully operator-dependent. The procedure is also associated with radiation exposure to patients and physicians. This study will evaluate the robotic assisted percutaneous coronary intervention as an alternative to manual operation.

  • Condition or Disease:Coronary Artery Disease
  • Intervention/Treatment: Procedure: Robotic Assisted Percutaneous Coronary Intervention
  • Phase: N/A
Detailed Description


Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 83 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Robotic-Assisted Percutaneous Coronary Intervention - A Safety and Effectiveness Study Applied to the Brazilian Public Health System
  • Estimated Study Start Date: June 2019
  • Estimated Primary Completion Date: February 2020
  • Estimated Study Completion Date: March 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Robotic Assisted Percutaneous Coronary Intervention
Procedure: Robotic Assisted Percutaneous Coronary Intervention
Robotic Assisted Percutaneous Coronary Intervention
Outcome Measures
  • Primary Outcome Measures: 1. Procedure Complications [ Time Frame: 1 day ]
    Death or non-fatal major acute complications on the target vessel (thrombosis, myocardial infarction, perforation or non-planned invasive treatment).
  • 2. Procedure Success [ Time Frame: 1 day ]
    Robotic Assisted Procedure Success
  • Secondary Outcome Measures: 1. Occurence of Major Events [ Time Frame: 1 month ]
    Death, stent thrombosis, Myocardial Infarction, Stroke
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Age> = 18 years;

2. Symptomatic ischemic heart disease and / or objective evidence of myocardial ischemia
with one or more target lesions;

3. Elective for percutaneous procedure (i.e. performed in a non-urgent context)

4. The target lesion (s) must be obstructive, with stenosis diameter > 50% (visual

5. The interventional planning of all target lesions should include robotic manipulation
in at least one treatment, as judged by the operator;

6. Acceptable candidate for myocardial revascularization surgery.

Exclusion Criteria:

1. ST-segment elevation myocardial infarction in the last 48 hours before the index

2. Ejection fraction 2.0 mg / dL) or calculated creatinine clearance
<30 ml / min; 4. Platelet count 700,000 cells / mm 3;

5. Total Leucocytes count 50%);

4. Angiographic thrombus;

5. Target lesion in surgical graft;

6. Total occlusion (TIMI 0 or 1 anterograde flow)

Contacts and Locations

Contact: Pedro Lemos, PhD +55 (11) 2151-4306 pedro.lemos@einstein.br

Sponsors and Collaborators

Hospital Israelita Albert Einstein

More Information
  • Responsible Party: Hospital Israelita Albert Einstein
  • ClinicalTrials.gov Identifier: NCT03927560 History of Changes
  • Other Study ID Numbers: Robotic First
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: May 1, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Coronary Artery Disease